NCT06075537Phase 2, phase 3Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Study sponsor: Denali Therapeutics Inc. · DNLI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants99Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview